NKGEN BIOTECH
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 63
- Market Cap
- -
- Website
- http://www.nkgenbiotech.com
- Introduction
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency...
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06189963
- Locations
- 🇺🇸
Valiance Clinical Research, Tarzana, California, United States
🇺🇸Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸Behavioral Research Specialists, LLC, Glendale, California, United States
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05990920
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Angeles Clinic and Research Institute, Los Angeles, California, United States
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05099549
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04678453
- Locations
- 🇲🇽
Hospital Angeles Tijuana, Tijuana, Baja California, Mexico
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- NKGen Biotech, Inc.
- Registration Number
- NCT04464967
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03941262
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
- Conditions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03894579
- Locations
- 🇲🇽
Hospital Angeles, Tijuana, BC, Mexico